Durvalumab in the treatment of non‑small cell lung cancer
01/2020 Special Edition
MUDr. Ondřej Bílek
Klinika komplexní onkologické péče, MOÚ, Brno
Lung cancer represents the leading cause of cancer death worldwide. Most of the patients are diagnosed with advanced disease. Targeting immune-checkpoint inhibitors represents a standard option for advanced non-small cell lung cancer. The aim of this review is to summarize and discuss the clinical evidence for the use of durvalumab in advanced NSCLC.
non-small cell lung cancer, chemo-radiation therapy, immunotherapy, durvalumab
The full article is only available to subscribers
Become a regular subscriber to our Oncological Review...